Hematology/Oncology News

In this video, Ronny Drapkin, MD, discusses the importance of increasing ovarian cancer awareness in PCPs and OB/GYNs.

In this video, Ronny Drapkin, MD, discusses identifying patients at heightened risk for ovarian cancer.

Editor’s note: This is the second in a series of five stories from ASCO Voices, a session during ASCO Annual Meeting that focused on the human side of oncology.

In this video, Ronny Drapkin, MD, discusses known risk factors for ovarian cancer.

In this video, Ronny Drapkin, MD, discusses how PARP inhibitors changed the field of ovarian cancer treatment.

In this video, Ronny Drapkin, MD, discusses recent advancements in ovarian cancer.

In this video, Ronny Drapkin, MD, discusses challenges in diagnosing ovarian cancer.

Several hematologists will be honored during this year’s ASH Annual Meeting.

A randomized phase 3 trial designed to evaluate xevinapant with chemoradiotherapy as treatment for certain patients with head and neck cancers has been discontinued due to likely lack of benefit, according to the agent’s manufacturer.

Prior radiotherapy was associated with progression-free survival in patients with metastatic cutaneous squamous cell carcinoma treated with cemiplimab, according to a study.